HonCode

Go Back   HER2 Support Group Forums > General Cancer News
Reload this Page Erbitux can now be used in Japan as 1st-line treatment for mCRC: Merck Serono
Register Gallery FAQ Members List Calendar Today's Posts

General Cancer News Latest Breast Cancer News from Moreover Technologies

 
 
Thread Tools Display Modes
Prev Previous Post   Next Post Next
Old 03-29-2010, 12:40 AM   #1
News
Senior Member
 
News's Avatar
 
Join Date: Oct 2007
Posts: 20,104
Erbitux can now be used in Japan as 1st-line treatment for mCRC: Merck Serono
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that Erbitux® (cetuximab) can now be used in Japan in combination with chemotherapy in the 1st-line treatment for patients with epidermal growth factor receptor -expressing, curatively unresectable (inoperable), advanced or recurrent colorectal cancer carrying the KRAS wildtype gene.

More...
News is offline   Reply With Quote
 

« Previous Thread | Next Thread »

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts
BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump


All times are GMT -7. The time now is 02:28 PM.
Contact Us - HER2 Support Group - Archive - Privacy Statement - Top

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter